Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis

Immunocompromised patients are at risk of developing toxoplasma encephalitis (TE). Standard therapy regimens (including sulfadiazine plus pyrimethamine) are hampered by severe side effects. While atovaquone has potent in vitro activity against Toxoplasma gondii, it is poorly absorbed after oral admi...

Descrición completa

Detalles Bibliográficos

Publicado en:	Antimicrob Agents Chemother
Principais autores:	Schöler, Nadja, Krause, Karsten, Kayser, Oliver, Müller, Rainer H., Borner, Klaus, Hahn, Helmut, Liesenfeld, Oliver
Formato:	Artigo
Idioma:	Inglês
Publicado:	American Society for Microbiology (ASM) 2001
Assuntos:	Experimental Therapeutics
Acceso en liña:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90544/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11353624/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.6.1771-1779.2001
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!